Titan Pharmaceuticals Enters Material Agreement
| Field | Detail |
|---|---|
| Company | Titan Pharmaceuticals Inc |
| Form Type | 8-K |
| Filed Date | Jun 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
Titan Pharma signed a big deal, filed financials, and sold some stock. Details to follow.
AI Summary
Titan Pharmaceuticals, Inc. announced on June 24, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on June 27, 2025.
Why It Matters
This filing indicates a significant business development for Titan Pharmaceuticals, potentially impacting its financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks that are not fully detailed in an 8-K.
Key Players & Entities
- Titan Pharmaceuticals, Inc. (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- June 27, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-13341 (company_id) — SEC File Number
- 94-3171940 (company_id) — I.R.S. Employer Identification No.
FAQ
What is the nature of the material definitive agreement entered into by Titan Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into on June 24, 2025.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
When were the financial statements and exhibits filed?
The financial statements and exhibits were filed as part of the 8-K report on June 27, 2025.
What is Titan Pharmaceuticals' principal executive office address?
The principal executive offices are located at 10 East 53rd St., Suite 3001, New York, NY 10022.
What is the company's telephone number?
The registrant's telephone number is (786) 769-7512.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding TITAN PHARMACEUTICALS INC.